FR940705-2-00138 FR940705-2-00090 Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(c). Promulgating and amending a list of classes of recombinant DNA molecules to be exempt from the NIH Guidelines because they consist entirely of DNA segments from species that exchange DNA by known physiological processes or otherwise do not present a significant risk to health or the environment; Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(d). Permitting experiments specified by Section III&hyph;A; Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(e). Certifying new host-vector systems with the exception of minor modifications of already certified systems (the standards and procedures for certification are described in Appendix I&hyph;II). Minor modifications constitute (e.g., those of minimal or no consequence to the properties relevant to containment); and Section IV&hyph;C&hyph;1&hyph;b&hyph;(1)&hyph;(f). Adopting other changes in the NIH Guidelines. Section IV&hyph;C&hyph;1&hyph;b&hyph;(2). Minor Actions NIH/ORDA shall carry out certain functions as delegated to it by the NIH Director (see Section IV&hyph;C&hyph;3). Minor Actions (as determined by NIH/ORDA in consultation with the RAC Chair and one or more RAC members, as necessary) will be transmitted to the RAC and Institutional Biosafety Committee Chairs: Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(a). Reviewing and approving certain experiments involving the deliberate transfer of recombinant DNA or DNA or RNA derived from recombinant DNA into one or more human subjects that qualify for the Accelerated Review process (see Section III&hyph;B&hyph;2); Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(b). Reviewing and approving minor changes to human gene transfer protocols under Section III&hyph;A&hyph;2 and III&hyph;B&hyph;2; Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(c). Changing containment levels for experiments that are specified in Section III; Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(d). Assigning containment levels for experiments not explicitly considered in the NIH Guidelines; and Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(e). Revising the Classification of Etiologic Agents for the purpose of these NIH Guidelines (see Section V&hyph;A). Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(f). Interpreting the NIH Guidelines for experiments to which the NIH Guidelines do not specifically assign containment levels; Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(g). Setting containment under Sections III&hyph;C&hyph;1&hyph;d and III&hyph;C&hyph;2&hyph;b; Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(h). Approving minor modifications of already certified host-vector systems (the standards and procedures for such modifications are described in Appendix I&hyph;II); Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(i). Decertifying already certified host-vector systems; Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(j). Adding new entries to the list of molecules toxic for vertebrates (see Appendix F); and Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(k). Determining appropriate containment conditions for experiments according to case precedents developed under Section IV&hyph;C&hyph;1&hyph;b&hyph;(2)&hyph;(c). The amended version of Section IV&hyph;C&hyph;2 reads as follows: Section IV&hyph;C&hyph;2. Recombinant DNA Advisory Committee (RAC). The RAC shall be responsible for advising the Director, NIH, on the actions listed in Section IV&hyph;C&hyph;1&hyph;b&hyph;(1). The amended version of Section IV&hyph;C&hyph;3 reads as follows: Section IV&hyph;C&hyph;3. Office of Recombinant DNA Activities (ORDA)
